Home Cart Sign in  
Chemical Structure| 1184173-73-6 Chemical Structure| 1184173-73-6

Structure of MK-8353
CAS No.: 1184173-73-6

Chemical Structure| 1184173-73-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

MK-8353, also known as SCH900353, is a potent and orally active ERK1/2 inhibitor and anticancer drug candidate currently being developed by Schering-Plough. MK-8353 exhibited comparable potency with SCH772984 across various preclinical cancer models.

Synonyms: SCH900353

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of MK-8353

CAS No. :1184173-73-6
Formula : C37H41N9O3S
M.W : 691.85
SMILES Code : O=C([C@@]1(SC)CN(CC(N2CC=C(C3=CC=C(C4=NN(C)C=N4)C=C3)CC2)=O)CC1)NC5=CC6=C(NN=C6C7=CC=C(OC(C)C)N=C7)C=C5
Synonyms :
SCH900353
MDL No. :N/A
InChI Key :KPQQGHGDBBJGFA-QNGWXLTQSA-N
Pubchem ID :58282870

Safety of MK-8353

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of MK-8353

MAPK

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01358331 Tumor, Solid PHASE1 TERMINATED 2014-05-20 -
NCT03745989 Solid Tumors Phase 1 Not yet recruiting May 6, 2022 -
NCT02972034 Neoplasms Col... More >>orectal Cancer Less << Phase 1 Recruiting October 29, 2021 United States, Michigan ... More >> Call for Information (Investigational Site 0002) Recruiting Grand Rapids, Michigan, United States, 49546 United States, Tennessee Call for Information (Investigational Site 0001) Recruiting Nashville, Tennessee, United States, 37203 Canada, Quebec Merck Canada Recruiting Kirkland, Quebec, Canada, H9H 4M7 Contact: Medical Information Centre Centre d'information medicale Merck Canada Inc.    514-428-8600 / 1-800-567-2594 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.45mL

0.29mL

0.14mL

7.23mL

1.45mL

0.72mL

14.45mL

2.89mL

1.45mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories